gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · RXRXHealthcareBiotechnology

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX)

$3.88+5.43%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.88▼ 22.40% in range
Nov 4, 2025Low $2.84 · High $5.00Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Recursion Pharmaceuticals closed at $3.88 on Nov 4, up 5.43%, 28.7% below its 52-week closing high. Volume of 20.6M shares was 0.77× its 20-day average (below normal).

Split-adjusted performance: -16.2% over one month, +13.1% over six months, -28.7% over one year.

In the quarter ended Sep 30, 2026, revenue was $18.55M, up 258.5% from a year earlier, with a net margin of -641.6%.

Short interest was 161.9M shares at the Oct 15 settlement, up 2.5% from the prior report (37.5% of float, 4.4 days to cover).

Market cap$2.32B597.8M shares
Revenue · quarter$18.6M+258.5% YoY
Diluted EPS$-0.22—
P/E · TTM—P/S 34.0×
Net margin-641.6%Gross 45.9%
Dividend yieldNone
52-week range2.84 – 5.44−28.7% from high
Volume20.6M0.77× 20-day avg
Volatility · 60d95.9%Annualised
Short % of float37.5%4.4 days to cover
Net cash$538.0MCash $549.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −10.8%1M −16.2%3M +22.0%6M +13.1%YTD −5.1%1Y −28.7%3Y −26.9%5Y −79.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum74
Revenue growth87
Net margin38
Value (low P/E)—
Size80

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short161.9M+2.5% vs prior
Days to cover4.4Settled Oct 15
% of float37.5%
Short vol. 10d45.2%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
RXRXRecursion Pharmaceuticals$3.88+5.43%+13.1%+258.5%−641.6%—$2.32B
VCELVericel$45.48+10.68%+23.7%+22.5%2.8%96.2$2.33BCompare
ADMAADMA Biologics$10.48−5.67%+4.0%+2.0%30.4%13.9$2.35BCompare
COAGHemab Therapeutics Holdings$45.09+4.62%————$2.11BCompare
BCRXBioCryst Pharmaceuticals$8.24−3.85%−6.7%+33.6%35.9%—$2.11BCompare
VIRVir Biotechnology$11.77+4.90%+14.4%+19582.5%33.5%—$1.99BCompare
REPLReplimune Group$20.69+0.19%+501.5%———$1.96BCompare
BEAMBeam Therapeutics$27.79+5.54%−14.1%−94.2%−25036.3%—$2.87BCompare
MAZEMaze Therapeutics$33.38+3.50%+26.1%———$1.85BCompare

News about Recursion Pharmaceuticals

All news →
RXRX Q3 Earnings Call Highlights Clinical Progress and Cash RunwayZacks Investment Research · 17h ago▲ PositiveRecursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · 2d agoNeutralRecursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsZacks Investment Research · 5d agoNeutralRecursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?Zacks Investment Research · 6d ago▲ PositiveRecursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to ConsiderZacks Investment Research · Oct 26, 2026Neutral

Quick answers

What does Recursion Pharmaceuticals do?
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
What is RXRX's market cap?
$2.32B, based on the Nov 4 close of $3.88.
Does Recursion Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of RXRX is sold short?
161.9M shares, 37.5% of float, as of Oct 15, 2026.
What sector is RXRX in?
Healthcare, in the Biotechnology industry.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

HQ: Salt Lake City, UT600 employeesListed Apr 16, 2021recursion.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology